Skip to main content
OpenTrials
Completed

NCT Number: NCT00068822

Vertebroplasty for the Treatment of Fractures Due to Osteoporosis

Vertebroplasty is a procedure used to stabilize broken vertebrae, the bones that form the spine. This study will evaluate the effectiveness of vertebroplasty for the treatment of fractures due to osteoporosis.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Spontaneous, atraumatic compression fractures due to osteoporosis occur in more than 700,000 patients per year. Pain associated with these fractures may be excruciating, but before the advent of percutaneous vertebroplasty, treatment options were limited. Analgesic medications, bed rest, and bracing have been the mainstays of treatment, but each of these therapies has substantial limitations.

Because of the dearth of viable treatment options for osteoporotic vertebral compression fractures, the practice of percutaneous vertebroplasty, which involves injection of polymethylmethacrylate (medical cement) into the fractured vertebra, has disseminated rapidly. However, evidence for the efficacy of percutaneous vertebroplasty is currently limited to uncontrolled, nonblinded, small case studies. Even though high rates of success are reported, with up to 90% of patients achieving substantial pain relief, these case studies have not accounted for numerous important potential biases, including the natural tendency for compression fractures to heal spontaneously, regression toward the mean (wherein patients seek medical attention when pain is maximum), and the placebo effect. This study will examine the clinical efficacy of percutaneous vertebroplasty for treatment of painful osteoporotic vertebral compression fractures.

Participants in this study will be randomly assigned to receive either percutaneous vertebroplasty or a sham procedure (placebo control group). Participants may have up to 2 spinal levels treated. Participants will be enrolled in the study for 1 year and will have study visits at entry and Months 1 and 12. There will also be phone visits at Days 1, 2, 3, and 14 and Months 3 and 6. After Month 1, crossover from the placebo group to the vertebroplasty group will be allowed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed osteoporosis or osteopenia by a referring physician and/or medical history and physical exam OR osteopenia on plain film
  • Vertebral compression fracture in vertebrae T4 through L5, of less than 1 year old
  • Pain not responsive to standard medical therapy
  • Current rating for pain intensity of at least 3 on a scale of 0 to 10

Exclusion criteria

  • Evidence or suspicion of malignant tumor or spinal canal compromise
  • Concomitant hip fracture
  • Local or systemic infection
  • Uncorrectable bleeding diatheses
  • Surgery within the previous 60 days
  • Lack of access to telephone
  • Inability to communicate in English
  • Dementia
  • Pregnancy
  • Abnormal renal function or anticipated venography
  • Conscious sedation is contraindicated for subject

Treatment and study plan

Percutaneous vertebroplasty

Device

Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture

Sham vertebroplasty

Procedure

Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.

Primary outcomes

  1. Back-specific Functional Status Using Roland-Morris Disability Questionnaire (RDQ) Scale at 1 Month

    Time frame: 1 month after procedure

    Back-specific functional status using RDQ scale range from 0 (no pain) to 23, with higher scores indicating more severe disability.

  2. Patient's Rating of Average Pain at 1 Month

    Time frame: 1 month

    Patient's rating of average pain intensity during the preceding 24 hours at 1 month. The rating scale was from 0 to 10, with higher scores indicating more severe pain.

Secondary outcomes

  1. Patient Well-being at 1 Month

    Time frame: Month 1

    Patient well-being was quantified by these tools: Health status outcome using Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36). Scores on the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36), version 2. Subjects completed the SF-36 which consists of 8 sub-scales which are additionally summarized into 2 summary components (physical and mental). The subscales and the summary scales both range from 0 to 100, with (0 = worst imaginable, 100 = best imaginable).

    Pain Frequency Index, Pain Bothersome Index (scores range from 0-4, higher scores indicating more severe pain).

    European Quality of Life (QOL) 5 Dimensions (EQ-5D), scale range -0.1 to 1.0; higher scores indicating a better QOL.

    Study of Osteoporotic Fractures-Activities of Daily Living (SOF ADL6) range from 0 to 18; higher scores = more back-related disability.

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

  • National Center for Research Resources (NCRR)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Registry information

Official study title

Investigational Vertebroplasty Efficacy and Safety Trial (INVEST)

Important dates

Study start
2003
Primary completion
2009
Study completion
2009
First posted
Sep 11, 2003
Registry last updated
Sep 27, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.